1. Home
  2. BANR vs GLPG Comparison

BANR vs GLPG Comparison

Compare BANR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banner Corporation

BANR

Banner Corporation

HOLD

Current Price

$64.12

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$29.04

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANR
GLPG
Founded
1890
1999
Country
United States
Belgium
Employees
N/A
704
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
BANR
GLPG
Price
$64.12
$29.04
Analyst Decision
Buy
Buy
Analyst Count
6
2
Target Price
$69.80
$36.50
AVG Volume (30 Days)
177.5K
193.7K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
3.13%
N/A
EPS Growth
15.57
N/A
EPS
5.64
N/A
Revenue
N/A
N/A
Revenue This Year
$0.73
N/A
Revenue Next Year
$5.69
N/A
P/E Ratio
$11.26
N/A
Revenue Growth
N/A
N/A
52 Week Low
$57.05
$24.74
52 Week High
$69.83
$37.78

Technical Indicators

Market Signals
Indicator
BANR
GLPG
Relative Strength Index (RSI) 60.24 41.92
Support Level $63.47 $28.78
Resistance Level $65.21 $34.04
Average True Range (ATR) 1.20 0.55
MACD 0.13 0.16
Stochastic Oscillator 73.35 64.90

Price Performance

Historical Comparison
BANR
GLPG

About BANR Banner Corporation

Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho, and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: